Registered outcomes19

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 19 of 19

Download this page as JSON

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02767063/registered

API reference For AI assistants

List	Outcome	Time frame	Description
Primary	Cumulative incidence of patients achieving a deep molecular response	12 months	The cumulative incidence of patients achieving a deep molecular response defined by MR4.5 or deeper (BCR-ABLIS ≤ 0.0032 %) by 12 months
Secondary	Adverse events	12 Months	Adverse events
Secondary	The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms	24 months	The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms
Secondary	The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms	36 months	The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms
Secondary	The cumulative rate of patients achieving MR4.5 by 48 months in experimental and control arms	48 months	The cumulative rate of patients achieving MR4.5 by 48months in experimental and control arms
Secondary	The cumulative rate of patients achieving MR4 by 12months in experimental and control arms	12 months	The cumulative rate of patients achieving MR4 by 12,months in experimental and control arms
Secondary	The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms	24 months	The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms
Secondary	The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms	36 months	The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms
Secondary	The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms	48 months	The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms	12 months	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24months in experimental and control arms	24 months	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24, months in experimental and control arms
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms	36 months	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms	48 months	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms
Secondary	The rate of patients in treatment free remission during follow-up	48 months	The rate of patients in treatment free remission during follow-up
Secondary	Quantification of CML- and normal-CFU in bone marrow by clonogenic assays and RTQ- PCR	12 months
Secondary	Survival	48 months	Survival
Secondary	duration of response	48 months	duration of response
Secondary	event free survival	48 months	event free survival
Secondary	progression free survival	48 months	progression free survival